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condensate on endothelial-mediated vascular relaxation and oxidative stress in isolated mouse mesenteric
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These deleterious effects were associated with downregulation of vascular endothelial growth factor and
endothelial NO synthetase. Conclusions Our results suggest that miR-155 dysregulation may contribute
to the deleterious vascular effects of tobacco smoking.
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ORIGINAL RESEARCH
Inhibition of miR-155 Attenuates Detrimental 
Vascular Effects of Tobacco Cigarette 
Smoking
Giacomo Frati, MD*; Maurizio Forte, PhD*; Flavio di Nonno, MS; Antonella Bordin, PhD; Isotta Chimenti, PhD; 
Vittorio Picchio, PhD; Elena Cavarretta , MD, PhD; Rosita Stanzione, MS; Franca Bianchi, MS;  
Roberto Carnevale , PhD; Cristina Nocella, PhD; Sonia Schiavon , MS; Daniele Vecchio , MS;  
Simona Marchitti , MS; Elena De Falco, PhD; Speranza Rubattu, MD; Francesco Paneni, MD, PhD;  
Giuseppe Biondi-Zoccai, MD; Francesco Versaci, MD; Massimo Volpe, MD; Francesca Pagano, PhD†; 
Sebastiano Sciarretta , MD, PhD†
BACKGROUND: The role of microRNAs dysregulation in tobacco cigarette smoking–induced vascular damage still needs to be 
clarified. We assessed the acute effects of tobacco cigarette smoking on endothelial cell-related circulating microRNAs in 
healthy subjects. In addition, we investigated the potential role of microRNAs in smoking-dependent endothelial cell damage.
METHODS AND RESULTS: A panel of endothelial-related microRNAs was quantified in healthy subjects before and after smoking 
1 tobacco cigarette. Serum levels of miR-155 were found to be significantly increased shortly after smoking. We also observed 
a progressive and significant miR-155 accumulation in culture media of human endothelial cells after 30 minutes and up to 
4 hours of cigarette smoke condensate treatment in vitro without evidence of cell death, indicating that miR-155 can be re-
leased by endothelial cells in response to smoking stress. Cigarette smoke condensate appeared to enhance oxidative stress 
and impair cell survival, angiogenesis, and NO metabolism in human endothelial cells. Notably, these effects were abrogated 
by miR-155 inhibition. We also observed that miR-155 inhibition rescued the deleterious effects of cigarette smoke conden-
sate on endothelial-mediated vascular relaxation and oxidative stress in isolated mouse mesenteric arteries. Finally, we found 
that exogenous miR-155 overexpression mimics the effects of smoking stress by inducing the upregulation of inflammatory 
markers, impairing angiogenesis and reducing cell survival. These deleterious effects were associated with downregulation of 
vascular endothelial growth factor and endothelial NO synthetase.
CONCLUSIONS: Our results suggest that miR-155 dysregulation may contribute to the deleterious vascular effects of tobacco 
smoking.
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C
ardiovascular diseases still represent the most 
common cause of death in Western countries.1 
Among cardiovascular risk factors, tobacco 
smoking is one of the most relevant2 and is dramat-
ically associated with adverse cardiovascular events 
and cardiac death.3 It also promotes the onset of 
other cardiovascular risk factors, such as hyperten-
sion, atherosclerosis, and coronary heart diseases, 
thereby further increasing patient global risk pro-
file.2,4 Mechanistically, cigarette smoking directly 
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increases oxidative stress in endothelial cells, leading 
to endothelial dysfunction that represents the main 
pathophysiological substrate underlying the develop-
ment and progression of cardiovascular diseases.5,6 
However, the molecular mechanisms promoting the 
harmful effects of cigarette smoking on endothelial 
function still need to be fully clarified. The elucida-
tion of this aspect would be useful to develop new 
cardiovascular preventive strategies in subjects who 
smoke.
MicroRNAs are endogenous, small noncoding 
RNAs involved in the regulation of gene expres-
sion. They act as key regulators of several cellular 
processes, such as cell proliferation, death, differ-
entiation, and intercellular communication.7 It was 
demonstrated that circulating microRNAs contribute 
to the genesis and progression of vascular damage 
in response to stress.8 Moreover, microRNAs also 
emerged as important predictors for cardiovascu-
lar diseases.9–11 In this regard, different microRNAs 
were reported to be highly expressed in the blood of 
patients with acute myocardial infarction and to rep-
resent potential diagnostic and prognostic biomark-
ers in patients with coronary artery diseases.12–15
Dysregulation of circulating microRNAs was also 
found in the presence of main cardiovascular risk 
factors, such as diabetes mellitus, hypertension, and 
cardiac hypertrophy.16–18 However, the impact of acute 
tobacco smoking on circulating microRNAs and the 
possible role of microRNA in smoking-induced en-
dothelial damage are still not fully understood. In this 
study, we investigated the potential role of microRNA 
deregulation induced by smoke on endothelial cells 
and mouse vessels.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Patient Sample Collection and 
Experimental Design
Subject recruitment, participant characteristics, and 
experimental procedures were previously reported 
by Carnevale et al.6 In summary, serum samples for 
microRNA level evaluations were collected from 40 
healthy young (21 women, mean age 28±5.3) non-
smoker (n=20) and smoker (n=20) participants, free 
of any disease, just before and within 30  minutes 
after smoking 1 tobacco cigarette with a mean nic-
otine content of 0.6  mg according to the package 
label. Participants enrolled in the study gave informed 
consent prior to their inclusion. The protocol was ap-
proved by the local ethical committee and was per-
formed in compliance with the Declaration of Helsinki.
RNA Extraction and MicroRNA 
Quantification
Endothelial-related microRNAs, based on the avail-
able literature (Table S1), were quantified in cells as 
well as fluids (serum and cell culture supernatants). 
Fluid samples were centrifuged at 25 000g to remove 
debris, platelets, or cells, and RNA was extracted 
from 200  μL of serum/conditioned media using 
the Qiagen miRNeasy kit (Qiagen GmbH, Hilden, 
Germany) following the manufacturer’s instructions 
with further modifications. Syn-cel-miR-39 spike in 
synthetic RNA (Qiagen GmbH) was added to moni-
tor extraction efficiency and to normalize microRNA 
levels. miR-155 levels were quantified using absolute 
quantification. A standard curve was generated with 
a synthetic miR-155 RNA, and the copy number was 
determined according to the standard curve. Cellular 
RNA was extracted using the Qiagen miRNeasy kit 
following the standard procedure. The expression of 
microRNAs was assessed by real-time quantitative 
polymerase chain reaction using the Taqman mi-
croRNA assays as described elsewhere.19 Relative 
microRNA expression in vitro was calculated using 
small nuclear RNA (snRNA-U6) as endogenous con-
trol with the comparative 2−ΔΔCt method.20
Cell Cultures and Treatments
Cigarette smoke condensate (CSC) was purchased 
by Murty Pharmaceuticals (Lexington, KY) (stock 
CLINICAL PERSPECTIVE
What Is New?
• Circulating serum levels of miR-155 increase 
after smoking 1 cigarette in healthy subjects.
• Inhibition of miR-155 rescues the detrimental ef-
fects of smoking stress on endothelial function 
in vitro and ex vivo.
What Are the Clinical Implications?
• miR-155 may represent a valid biomarker for 
cardiovascular risk stratification of subjects who 
smoke.
Nonstandard Abbreviations and Acronyms
CSC cigarette smoke condensate
HUVECs human umbilical vein endothelial cells
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solution 40 mg/mL in DMSO) and diluted in cell me-
dium at the final concentration of 20 μg/mL, based 
on previous studies.21–23 Human umbilical vein en-
dothelial cells (HUVECs) (Lonza, Monza, Italy) were 
grown in EGM2 (Lonza) complete medium in a hu-
midified incubator at 37°C and 5% CO2. For CSC and 
H2O2 experiments, HUVECs were serum starved for 4 
hours using DMEM low-glucose medium (Lonza). The 
medium was then changed with DMEM low-glucose 
medium containing 20  μg/mL CSC or 100  μmol/L 
H2O2. Cells incubated in DMEM low-glucose medium 
with vehicle (DMSO <0.01%) were used as controls. 
HUVECs were harvested after 15  minutes, 30  min-
utes, 1 hour, 4 hours, and 12 hours of treatment (t=0). 
Cells between passages 2 and 4 were used for all the 
experiments.
Apoptosis
Apoptosis in CSC-treated or H2O2-treated HUVECs 
and respective control cells was evaluated by the 
Annexin V-FITC Apoptosis detection kit (eBioscience, 
San Diego, CA) according to the manufacturer’s pro-
tocol modified for adherent cells.24 Data were col-
lected using fluorescence-activated cell sorting (FACS) 
Calibur flow cytometer (BD Biosciences, San Jose, 
CA) and analyzed using FlowJo software (FlowJo LLC, 
Ashland, OR).
miR-155 Mimic Transfection in HUVECs
Transient transfection of miR-155 mimic (Sigma 
Aldrich-Merck, Darmstadt, Germany) was set up to 
obtain a final concentration of 10 and 50 nmol/L in the 
transfection media as suggested by the manufacturer. 
Transfection medium was replaced with EGM2 com-
plete medium after 5 hours, and the effect of miR-155 
mimic on endothelial function (cell viability, angiogene-
sis, gene expression, and protein levels) was assessed 
after 24 hours.
Anti-miR-155 Inhibition Experiments In 
Vitro
The effects of CSC (20 μg/mL) on endothelial function 
(cell viability, angiogenesis, and protein levels) were as-
sessed after 48 hours of treatment in the presence or 
absence of anti-miR 155 LNA (miRcury LNA microRNA 
inhibitor, Qiagen) used at a final 50 nmol/L concentra-
tion following the manufacturer’s instructions. Briefly, 
HUVECs were transfected with anti-miR-155 LNA di-
luted in Opti-MEM reduced serum medium (OPTIMEM) 
with lipofectamine transfection agent (Lipofectamine 
RNAimax, Invitrogen, Carlsbad, CA) for 5  hours. 
Transfection medium was then replaced with EGM2 
complete medium with or without CSC at the afore-
mentioned concentration.
MTT Assay
Cell survival was evaluated using the MTT reagent 
(Sigma Aldrich–Merck, Darmstadt, Germany). Control 
and treated HUVECs were incubated for 5 hours with 
MTT, and the absorbance of the solubilized substrate 
was measured with a microplate reader (Biorad, Milan, 
Italy) at 570 nm.
Matrigel Assay
Angiogenesis was performed by Matrigel assay. 
Briefly, Matrigel matrix growth factor reduced (BD 
Biosciences) was seeded in a 35-mm culture dish and 
allowed to solidify for 1  hour at 37°C. HUVECs col-
lected after each specific treatment (described previ-
ously) were seeded on top of the Matrigel layer and 
incubated for 24  hours. Images were taken with an 
optical microscope (Zeiss, Jena, Germany) fitted with 
a digital camera, and the number of branching points 
was quantified from 3 to 10 randomly chosen fields 
using ImageJ software (National Institutes of Health, 
Bethesda, MD).
Gene Expression Analyses
TNF-α (tumor necrosis factor α) and interleukin (IL)-
6 gene expressions were assessed in HUVECs by 
quantitative reverse transcriptase–polymerase chain 
reaction analysis. Total RNA was extracted by Trizol 
(Invitrogen, Milan, Italy), purified with DNAse and ret-
rotranscribed into cDNA using SuperScript VILO 
Master Mix (Invitrogen). Quantitative reverse tran-
scriptase–polymerase chain reaction analysis was 
performed using the ViiA7 Real-Time PCR System 
and SYBR Select Master Mix 2X (Applied Biosystem, 
Foster City, CA). miR-155 precursor gene (Pri-miR-155) 
(hBIC) expression was assessed by quantitative re-
verse transcriptase–polymerase chain reaction analy-
sis using validated primers25 for the amplification of 
the unprocessed transcript encoding for miR-155. 
The amount of cDNA target was normalized using 
GAPDH (glyceraldehyde 3-phosphate dehydroge-
nase) as housekeeping gene and calculated by the 
comparative 2−ΔΔCt method.20 Used primers were as 
follows: TNF-α sense: CATCTTCTCGAACCCCGAGT; 
TNF-α antisense: CACCAGCTGGTTATCTCTCA; IL-6  
sense: GCTGCAGGCACAGAACCA; IL-6 antisense: GC 
TGCGCAGAATGAGATGAG; hBIC sense: ACCAGAGAC 
CTTACCTGTCACCTT; hBIC antisense: GGCATAAAG 
AATTTAAACCACAGATTT; GAPDH sense: CAAGGCT 
GTGGGCAAGGT; GAPDH antisense: GGAAGGCCAT 
GCCAGTGA.
Western Blot Analysis
Samples were lysed in radioimmunoprecipitation 
assay buffer, separated by SDS-PAGE and transferred 
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onto polyvinylidene difluoride membranes (Amersham, 
Piscataway, NJ). Membranes were blocked in 5% non-
fat dried milk (Biorad) and incubated overnight with 
the following primary antibodies: vascular endothelial 
growth factor (VEGF) (Abcam, Cambridge, UK), en-
dothelial NO synthetase (Cell Signaling Technology, 
Danvers, MA), GAPDH (Santa Cruz Biotechnology, 
Santa Cruz, CA), and β-Actin (Santa Cruz). Detection 
was performed using ECL prime (Amersham 
Biosciences, CA).
H2O2 and NO Detection
H2O2 production and NO metabolites nitrite and ni-
trate were detected in HUVECs conditioned media 
by commercially available kits (Arbor Assay, Ann 
Arbor, MI). Experiments were performed following 
the manufacturer’s protocol and values were ex-
pressed in μmol/L.
Animal Studies
Vascular reactivity experiments were performed on 
mesenteric arteries isolated from 8-week-old male 
wild-type mice (C57BL6/J, N=6). Vessels were placed 
in a pressure myograph system filled with Krebs so-
lution and transfected for 6 hours with 50  nmol/L 
of a mouse-specific anti-miR-155 LNA (miRcury 
LNA microRNA inhibitor, Qiagen) in the presence of 
the transfection reagent (Lipofectamine RNAimax, 
Invitrogen, Carlsbad, CA). Control vessels were in-
cubated with a mouse-specific anti-miR negative 
control (miRCURY LNA microRNA Inhibitor Control, 
Qiagen). Vasorelaxation was assessed by meas-
uring the dilatory responses of mesenteric arteries 
to cumulative concentrations of acetylcholine (from 
10−9 to 10−5  mol/L) in vessels precontracted with 
phenylephrine as previously reported.26 Responses 
were assessed after incubation with or without CSC 
treatment (1  μg/mL) for 1  hour. Oxidative stress 
levels in vessels was assessed by dihydroethidium 
staining (Sigma Aldrich) as previously described.27 
Fluorescence intensity was quantified by ImageJ 
software. All studies involving animals were per-
formed in accordance with the Italian and European 
Community (Directive 2010/63/EU) for animal experi-
ments, and the protocol was approved by Sapienza 
University Animal Care Review Board. Mice were 
euthanized by cervical dislocation, and vessels were 
isolated for vascular reactivity experiments.
Statistical Analysis
Results are reported as mean±SEM of independ-
ent experiments. In vitro experiments were per-
formed at least 3 times, and nonparametric tests 
were used for comparisons because of the small 
number of independent replicates in different groups. 
Comparisons between 2 groups were performed 
by Mann–Whitney nonparametric tests. Statistical 
analysis between multiple groups was performed 
by Kruskal–Wallis nonparametric test followed by 
Conover post hoc analysis.
For human subject analyses, microRNA serum 
level significance was assessed by the Wilcoxon 
signed-rank test (matched pairs) for non-normalized 
values. On the other hand, 1-sample Student t tests 
were performed for miR-155–fold change in serum 
samples after checking for normal distribution of the 
values.
In ex vivo mouse experiments, 2-way analysis of 
variance followed by the Tukey multiple comparisons 
test was used for vascular reactivity assessment.
Graph Pad Prism software (GraphPad Software, Inc. 
La Jolla, CA), (MedCalc statistical software, MedCalc 
Software Ltd, Ostend, Belgium), and the R statis-
tic package (R Foundation for Statistical Computing, 
Vienna, Austria) were used for the statistical analyses, 
and statistical significance was set at the 2-tailed 0.05 
level.
RESULTS
We quantified the expression levels of several en-
dothelial-related microRNAs based on the available 
literature8,9,28,29 (listed in Figure  1A and Table  S1) in 
sera obtained from 40 healthy subjects before and 
after smoking 1 tobacco cigarette. Raw data analy-
sis was performed on the linearized cycle threshold 
(Ct) value (2−Ct) to assess the overall detection level 
of each miRNA. Some microRNAs were not detect-
able and were therefore excluded from further analysis 
(Figure 1A). We compared the detection level of each 
microRNA in each subject and found that miR-155 
was the only microRNA to be significantly affected by 
smoking, with a significant increase of its circulating 
levels after a cigarette consumption (Figure 1A and 1B). 
Normalized expression levels also confirmed this re-
sult, showing a 1.8-fold increase of circulating miR-155 
levels in the study subjects after smoking 1 cigarette 
(Figure 1C).
To test whether endothelial cells may represent a 
possible origin of circulating miR-155 after cigarette 
smoking, we tested whether CSC could induce miR-
155 release in cultured endothelial cells. We therefore 
used HUVECs treated with CSC to mimic smoking 
stress in vitro and measured the intracellular and ex-
tracellular levels of miR-155 after 30 minutes, 1 hour, 
4 hours, and 12 hours of treatment. We found that miR-
155 levels significantly increased in culture medium of 
cells treated with CSC over time with respect to con-
trol cells (Figure  2A), without evidence of increased 
J Am Heart Assoc. 2020;9:e017000. DOI: 10.1161/JAHA.120.017000 5
Frati et al Cigarette Smoking and Circulating MicroRNAs
cellular damage or membrane disruption up to 4 hours 
(Figure 2D). On the other hand, FACS analysis revealed 
an increased apoptosis after 12 hours in CSC-treated 
cells, suggesting that miR-155 extracellular accumu-
lation may also be attributable to membrane alter-
ations or cell disruption after prolonged CSC treatment 
Figure 1. Cigarette smoke increases circulating miR-155 levels in healthy subjects.
A, Table listing the assessed microRNAs levels in sera before and after cigarette smoking. B, Dot 
plot showing quantitative polymerase chain reaction quantification of miR-155 relative copy number 
in paired samples from 40 individuals before and after smoking 1 cigarette. Mean±SEM (N=40); 
*P<0.05, obtained using the Wilcoxon signed-rank test, matched pairs for non-normalized values. C, 
Bar graph showing cel-39 normalized miR-155 relative average fold change after smoking 1 cigarette 
(after) with respect to baseline levels (before) in the study population. Mean±SEM (N=40). *P<0.05, 
obtained using the Student t test. NA indicates not applicable; n.d., not detectable; and ns, not 
significant.
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Figure 2. Cigarette smoke condensate (CSC) increases miR-155 in human umbilical vein 
endothelial cells.
A, Graph showing quantification of extracellular miR-155 (copy number) in cell culture supernatants 
collected from cigarette smoke condensate (CSC)–treated cells (red line) and DMSO-treated (control 
[CTR]) cultures (black line) at the indicated time points. CSC was used at 20 µg/ml concentration. **P<0.01 
and ***P<0.001 obtained by Kruskal–Wallis nonparametric test followed by Conover post hoc analysis. B 
and C, Bar graphs showing the intracellular miR-155 (B) and pri-miR-155 (C) relative expression measured 
in DMSO (CTR) and CSC-treated human umbilical vein endothelial cells at 4 and 12 hours. Gene expression 
was normalized to either U6 small nuclear RNA (snoRNA) or GAPDH for miR and pri-miR, respectively. 
*P<0.05 obtained by Kruskal–Wallis nonparametric test followed by Conover post hoc analysis. D and E, 
Bar graph showing the percentage of apoptotic human umbilical vein endothelial cells (Annexin V positive) 
at 4 (D) and 12 hours (E) in DMSO control (CTR) and CSC-treated cells. *P<0.05 obtained by Mann–
Whitney nonparametric test. All data are presented as mean±SEM (N=3–4). n.s. indicates not significant.
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(Figure 2E). For this reason, we did not evaluate miR-
155 accumulation at longer time points. We also ob-
served an increase in intracellular miR-155 levels after 
4  hours of treatment compared with untreated cells 
(Figure 2B). In contrast, we did not see an intracellular 
increase of miR-155 precursor gene (pri-miR-155) at 
the same time point (Figure 2C). Conversely, intracel-
lular miR-155 levels decreased after 12 hours of CSC 
treatment, suggesting that miR-155 is continuously 
synthetized, released, and probably up-taken by en-
dothelial cells in response to CSC treatment (Figure 2B 
and 2C).
Because smoking stress induces reactive oxygen 
species generation in endothelial cells, we assessed 
whether oxidative stress is sufficient to promote the 
extrusion of miR-155 by endothelial cells. Therefore, 
we treated HUVECs with 100 μmol/L H2O2 and ob-
served an increase in miR-155 accumulation in culture 
media of treated cells, in line with the results obtained 
with CSC treatment (Figure 3A and 3B).
We then tested whether miR-155 may contribute to 
the detrimental endothelial effects of smoking. For this 
purpose, we treated endothelial cells with CSC in the 
presence or absence of a specific inhibitor of miR-155. 
As expected, we found that CSC impaired angiogene-
sis (Figure 4A and 4B) and cell survival (Figure 4C) and 
drastically increased H2O2 (Figure 4D). Notably, these 
effects were attenuated by anti-miR-155 treatment 
(Figure 4A through 4D). Similarly, we also found a sig-
nificant reduction of endothelial NO synthetase expres-
sion levels (Figure 4E, Figure S1) and NO production 
(Figure 4F) in response to CSC treatment, which were 
rescued by anti-miR-155 (Figure 4E and 4F, Figure S1).
We also observed that miR-155 inhibition blunted 
CSC-induced reduction of vasorelaxation in re-
sponse to acetylcholine in isolated vessels from mice 
(Figure 5A) along with a significant reduction of oxida-
tive stress (Figure 5B and 5C).
These data suggest that miR-155 plays a role in 
mediating the deleterious effects of smoking stress in 
endothelial function both in vitro and ex vivo.
Finally, to further explore the biological significance 
of miR-155 accumulation by smoking stress, we eval-
uated the effects of its overexpression in endothelial 
cells by using a synthetic miR-155 mimic. We found 
that exogenous administration of miR-155 decreased 
cell viability (Figure 6A). In addition, miR-155 strongly 
impaired capillary network formation and reduced the 
number of branch points compared with untreated 
cells, indicating a reduced angiogenesis (Figure  6B 
and 6C). miR-155 mimic administration was also as-
sociated with increased gene expression of IL-6 and 
TNF-α (Figure 6D). Finally, we found that miR-155 ad-
ministration strongly reduced protein levels of VEGF 
and endothelial NO synthetase (Figure  6E and 6F; 
Figure S2A and S2B).
DISCUSSION
In our study, we demonstrated that smoking 1 single cig-
arette is sufficient to induce a rapid release of miR-155 
Figure 3. Oxidative stress increases extracellular miR-155 accumulation in human umbilical vein 
endothelial cells.
A, Bar graph showing the percentage of apoptosis in untreated control cells (CTR) and after 4 hours of 
treatment with 100 μmol/L H2O2 (H2O2). Mann–Whitney nonparametric test. B, Time course measurement 
of miR-155 levels during H2O2 treatment in cell lysates (blue line) and conditioned media (red line) showing 
fold change with respect to untreated cells at each time point. *P<0.05 compared to untreated cells 
(CTR) obtained by Kruskal–Wallis nonparametric test followed by Conover post hoc analysis. All data are 
presented as mean±SEM (N=3–4). n.s. indicates not significant.
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in the bloodstream of healthy individuals. We also ob-
served that smoke stress promotes the release of miR-
155 from endothelial cells. However, miR-155 extracellular 
accumulation after 12 hours may also be attributable to 
cellular damage because we observed increased apop-
tosis after 12 hours of CSC exposure. miR-155 inhibition 
Figure 4. Anti-miR-155 blunts the deleterious effects of CSC on angiogenesis, cell survival, 
H2O2, and NO metabolism in endothelial cells.
A and B, Representative images of human umbilical vein endothelial cells angiogenesis assessed 
by Matrigel assay (scale bar=50 μm) (A) and bar graph showing relative quantification of branch 
point number (B) (N=3). C, Bar graph showing the percentage of human umbilical vein endothelial 
cells viability in each condition measured by MTT assay. Viability of CTR was set as 100% (N=3) 
D, Bar graph showing H2O2 concentration in cell supernatants collected in each condition (N=3). 
E, Representative image of Western blot analysis of eNOS expression (1 of 3 similar experiments). 
F, NOx levels in cell supernatants (N=3–9). Cells were treated for 48  hours with 20 μg/mL CSC 
either in the presence or absence of 50 nmol/L anti-miR 155 (α-miR-155). *P<0.05 obtained by using 
nonparametric Kruskal-Wallis test followed by Conover post hoc analysis. All data are presented as 
mean±SEM. CSC indicates cigarette smoke condensate; CTR, DMSO-treated control cells; eNOS, 
endothelial NO synthetase; and NOx, NO metabolite.
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could rescue angiogenesis, cell survival, NO metabolism, 
and redox status in endothelial cells treated with CSC. It 
also restored vascular function and oxidative stress in iso-
lated arteries exposed to smoke stress. miR-155 mimic 
administration was also sufficient to mimic the effects of 
smoke stress. We also found that reactive oxygen species 
induced miR-155 release by endothelial cells, whereas 
miR-155 inhibition blunted oxidative stress both in vitro 
and ex vivo, suggesting a detrimental synergistic feed-
back loop between miR-155 and oxidative stress.
Our data extend previous evidence demonstrating 
the involvement of miR-155 in vascular pathophysiol-
ogy. Previous studies showed that inflammation and 
oxidative stress increase endothelial miR-155 expres-
sion, leading to endothelial dysfunction.30,31 Inhibition 
of miR-155 ameliorates endothelium-dependent relax-
ation.30 Remarkably, endothelial NO synthetase was 
shown to be a direct target of miR-155,30 whereas 
VEGF levels were inversely correlated with miR-155 
expression.32
Data obtained in preclinical and clinical stud-
ies reported a close association between miR-155 
plasma level and the development of cardiovascular 
diseases.33,34 For example, circulating miR-155 was 
suggested to have a prognostic value in patients with 
myocardial infarction and heart failure.35–38
Previous works attempted to address the impact 
of cigarette smoking on circulating microRNAs.39–41 
These studies demonstrated that smoking exposure 
induces a significant dysregulation in microRNAs 
Figure 5. Anti-miR-155 blunts the deleterious effects of CSC on endothelial relaxation and 
oxidative stress of mouse mesenteric arteries.
A, Mesenteric arteries from wild-type C57BL6/J mice were transfected ex vivo with 50 nmol/L anti-miR-155 
(α-miR-155) and incubated with 1 μg/mL cigarette smoke condensate (CSC) for 1 hour. Control vessels 
were incubated with 50 nmol/L anti-miR negative control (CTR) and treated with CSC. Light blue and 
black α-miR-155 and CTR lines, respectively, represent vessels without CSC treatment. *P<0.05, **P<0.01, 
and ***P<0.001 obtained by using 2-way analysis of variance followed by Tukey’s multiple comparison 
test. B and C, Representative images of dihydroethidium (DHE) staining and relative quantification (scale 
bar=100 μm). *P  < 0.05 obtained by nonparametric Kruskal-Wallis test followed by Conover post hoc 
analysis. All data are presented as mean±SEM (N=6).
J Am Heart Assoc. 2020;9:e017000. DOI: 10.1161/JAHA.120.017000 10
Frati et al Cigarette Smoking and Circulating MicroRNAs
plasma profile either in smokers or in former smokers. 
However, in these studies it was impossible to under-
stand whether the observed dysregulation of microR-
NAs was a direct consequence of smoke exposure or 
whether it was rather the consequence of smoke-re-
lated pathologies. In our study, we demonstrated for 
the first time that smoking 1 cigarette is sufficient to 
induce a rapid release of miR-155 in the bloodstream 
Figure 6. Exogenous miR-155 overexpression impairs cell survival, angiogenesis, inflammation 
and endothelial marker expression in human umbilical vein endothelial cells.
A, Bar graph showing the percentage of viable human umbilical vein endothelial cells treated with miR-
155 mimic for 24 hours. B, Representative images of human umbilical vein endothelial cell angiogenesis 
assessed by Matrigel assay after exposure to different concentrations of miR-155 mimic (10  nmol/L, 
50 nmol/L); scale bar=100 µm. C, Bar graph showing angiogenesis quantification as branchpoint count in 
each condition. D, Relative gene expression of IL-6 and TNF-α in human umbilical vein endothelial cells 
after miR-155 treatment for 24 hours. Fold change compared to CTR. E and F, Representative Western 
blot images of VEGF (E) and endothelial NO synthetase (eNOS) (F) in human umbilical vein endothelial 
cells transfected with miR-155 mimic. *P<0.05 compared to untreated cells (CTR) obtained using the 
nonparametric Kruskal-Wallis test followed by Conover post hoc analysis. All data are presented as 
mean±SEM (N=3). CTR indicates nontransfected control cells; eNOS, endothelial NO synthetase; IL-6, 
interleukin-6; TNF-α, tumor necrosis factor α; and VEGF, vascular endothelial growth factor.
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of healthy subjects free of any disease. Based on the 
observed detrimental effects of miR-155 in endothelial 
cells, we speculate that miR-155 increase after smok-
ing each tobacco cigarette may represent an insult on 
endothelial cells, contributing in the long-term to the 
development of protracted inflammation and endothe-
lial dysfunction. Future studies are warranted to test 
this hypothesis. However, this view is supported by our 
current results showing that the detrimental effects of 
smoking stress are attenuated by miR-155 inhibition.
It will also be interesting to test whether miR-155 
could represent a valid biomarker for the risk stratifica-
tion of subjects who smoke or for a proper evaluation 
of the safety profile of modified risk products, such as 
electronic cigarettes and heat-not-burn cigarettes.42
Several limitations in our study should also be ac-
knowledged. First, we did not conduct an unbiased 
large screening of circulating microRNA before and 
after tobacco smoking, whereas the choice of the stud-
ied microRNAs was based on the literature. In addition, 
we only tested the acute effects of tobacco smoking 
on miR-155 release in the bloodstream, and we did 
not evaluate whether this is chronically correlated with 
vascular damage in subjects who smoke. The effects 
of chronic cigarette smoking or different nicotine con-
tents on microRNAs expression need to be elucidated 
in future studies. Finally, when we analyzed the effects 
of acute smoking on circulating microRNA levels in our 
human samples, we did not correct for multiple testing 
because of the small sample size. However, we be-
lieve that our in vitro and ex vivo biological experiments 
substantiated the human results, fully confirming the 
involvement of miR-155 in the development of smok-
ing-induced endothelial damage.
In conclusion, our data suggest that miR-155 is in-
volved in the development of endothelial damage in-
duced by smoking stress.
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Figure S1. MiR-155 inhibition blunts the deleterious effects of CSC on eNOS 
expression. 
Densitometric analysis of western blot for eNOS in HUVECs incubated with 20 μg/mL CSC 
either in presence or absence of 50 nM anti-miR-155 (α-miR-155); CTR indicates untreated 
cells. *p<0.05; obtained by using the non-parametric Kruskal-Wallis test followed by 
Conover’s post-hoc analysis. All data are presented as mean +/- SEM (N=3). 
Figure S2. miR-155 overexpression decreases VEGF and eNOS expression. 
(A-B). Densitometric analyses of western blots for VEGF (A) and eNOS (B) in HUVECs 
treated with different concentrations of miR-155 mimic (10nM, 50nM). *p<0.05 obtained by 
using the non-parametric Kruskal-Wallis test followed by Conover’s post-hoc analysis. All 
data are presented as mean +/- SEM (N=3). 
